KMT2A and leukemia: Our finding that SID7969543 also targets CALM-AF10 translocated leukemia cells, supports previous reports showing that KMT2A and CALM-AF10 translocations rely on common underlying leukemogenic pathways (14–16) and further emphasizes that both leukemia subtypes share common targetable vulnerabilities.